Riskpilot← Back to searchSign inGet full accessCarera Pharma A/S
A/SActiveCVR 39913046Lyongade 21Retail sale of other food · NACE 4727Est. 20181 employeeswww.Carera.dk
Revenue 2024
DKK 302K
-70% vs 2023
EBITDA margin
-56.3%
-234% vs 2023
Equity ratio
-364.2%
Financial strength
Net profit 2024
DKK -501K
-22% vs 2023
| Revenue | DKK 302K | -70% |
| EBITDA | DKK -170K | -234% |
| Net profit | DKK -501K | -22% |
| Total assets | DKK 986K | -23% |
| Equity | DKK -3,6M | -16% |
| Employees | 1 | — |
Legal name
Carera Pharma A/S
CVR number
39913046
Legal form
Aktieselskab
NACE code
4727 · Retail sale of other food
Founded
3. oktober 2018
Share capital
DKK 400.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør eller bestyrelsen i forening.
Company purpose
Selskabets formål er at drive restaurant samt aktiviteter i tilknytning hertil.
Address
Lyongade 21
Phone
+4530567555
Email
wen@airstore.dk
Website
www.Carera.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 1.326 | 2.579 | 1.769 | -318 | 999 | 302 |
| Staff expenses | -1.488 | -2.738 | -2.104 | -1.369 | -1.050 | -472 |
| EBITDA | -163 | -159 | -335 | -1.686 | -51 | -170 |
| Depreciation & amort. | -56 | -162 | -184 | -186 | -186 | -145 |
| EBIT | -218 | -321 | -519 | -1.872 | -237 | -315 |
| Net financials | 0 | -44 | -84 | -154 | -175 | -52 |
| Profit before tax | -218 | -365 | -604 | -2.026 | -412 | -368 |
| Tax | -51 | -86 | 4 | -0 | -0 | 133 |
| Net profit | -167 | -278 | -607 | -2.026 | -412 | -501 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 1.534 | 1.777 | 1.293 | 1.126 | 1.275 | 986 |
| Equity | 233 | -46 | -653 | -2.680 | -3.091 | -3.592 |
| Long-term debt | 37 | 227 | 227 | 119 | 0 | 0 |
| Short-term debt | 1.264 | 1.596 | 1.719 | 3.686 | 4.366 | 4.578 |
| Total debt | 1.301 | 1.823 | 1.947 | 3.805 | 4.366 | 4.578 |
EBITDA margin
-56.3%
This company
15.8%
Market median
-456% vs market
20192024
Equity ratio
-364.2%
This company
38.2%
Market median
-1053% vs market
20192024
Return on equity
-50069000.0%
This company
18.4%
Market median
-272114230% vs market
20192024
Net profit margin
-165.8%
This company
8.1%
Market median
-2147% vs market
20192024
Asset turnover
0.31×
This company
1.12×
Market median
-72% vs market
20192024
Debt / equity
1.27×
This company
0.62×
Market median
-105% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-10-03 – 2019-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2018 | — | — | |
CL | Deputy Chairman | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 90.0% | 90.0% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Carera Pharma A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Chenglin Gu | Chairman | 0 companies |
| Chen Liu | Deputy Chairman | 0 companies |